Key result
P2Y12 de-escalation cuts major cardiovascular events ~24% in ACS patients.
Why the study?
The study assessed the effectiveness of precision medicine approaches—including platelet function testing, genetic testing, and uniform de-escalation—in individualizing P2Y12 de-escalation strategies for ACS patients undergoing PCI.
Do P2Y12 de-escalation strategies reduce MACE and bleeding events in ACS patients undergoing PCI compared to standard potent P2Y12 inhibitor therapy?
Do P2Y12 de-escalation strategies reduce MACE and bleeding events in ACS patients undergoing PCI compared to standard potent P2Y12 inhibitor therapy?
P2Y12 de-escalation strategies, particularly uniform unguided de-escalation, significantly reduce MACE and bleeding events in ACS patients post-PCI compared to standard potent P2Y12 inhibitor therapy.
Answers are grounded in this paper and cite their sources.
May inform individualized P2Y12 de-escalation post-ACS PCI; leaves open need for prospective RCTs before practice change.
This comprehensive literature review assessed the effectiveness of precision medicine approaches in individualizing P2Y12 de-escalation strategies, such as platelet function testing guidance, genetic testing guidance, and uniform de-escalation, for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Analyzing six trials with a total of 13,729 patients, the cumulative analyses demonstrated a significant reduction in major adverse cardiac events (MACE), net adverse clinical events (NACE), and major and minor bleeding events with P2Y12 de-escalation. Specifically, the analysis found a 24% reduction of MACE and a 22% reduction of adverse event risk (relative risk (RR) 0.76, 95% confidence interval (CI): 0.71-0.82, and RR: 0.78, 95% CI 0.67-0.92, respectively). Reductions in bleeding events were highest with uniform unguided de-escalation, followed by guided de-escalations, while ischemic event rates were similarly lower across all three strategies. Although the review highlights the potential of individualized P2Y12 de-escalation strategies to offer a safer alternative to the long-term potent P2Y12 inhibitor-based dual antiplatelet therapy, it also indicates that laboratory-guided precision medicine approaches may not yet offer the expected benefits, necessitating further research to optimize individualized strategies and evaluate the potential of precision medicine approaches in this context.
No takes yet. Share an insight, caveat, or question.
Abdallaoui et al. (2023) conducted a review in Acute coronary syndrome (ACS) (n=13,729). P2Y12 de-escalation strategies vs. Long-term potent P2Y12 inhibitor-based dual antiplatelet therapy was evaluated on Major adverse cardiac events (MACE) (RR 0.76, 95% CI 0.71-0.82). P2Y12 de-escalation strategies reduced major adverse cardiac events and net adverse clinical events in ACS patients.
Synapse has enriched 10 related papers. Consider them for comparative context: